CID 10154225

Base Information

• Chemical Name: CID 10154225
• CAS No.: 76584-70-8
• Molecular Formula: C16H31NaO4
• Molecular Weight: 310.40
• Hs Code.: 2915900000
• Mol file: 76584-70-8.mol

Synonyms:SCHEMBL244738

Chemical Property of CID 10154225

Chemical Property:

• Appearance/Colour: a white powder with a characteristic odor
• Vapor Pressure: 0.0435mmHg at 25°C
• Melting Point: 222 °C
• Boiling Point: 220 °C at 760 mmHg
• Flash Point: 116.6 °C
• PSA: 77.43000
• LogP: 3.24010
• Storage Temp.: Refrigerator
• Solubility.: Chloroform (Slightly), Methanol (Slightly)
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 5
• Exact Mass: 167.10479903
• Heavy Atom Count: 11
• Complexity: 93.4

Purity/Quality:

99% ^*data from raw suppliers

ValproicAcidSemisodiumSalt ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCCC(CCC)C(=O)O.[Na]
• Description: Divalproex is a prodrug form of valproic acid that contains valproic acid and valproate sodium. Formulations containing divalproex exhibit delayed gastrointestinal absorption and are converted to valproic acid in the intestine, which reduces gastric irritation and nervous system side effects. Formulations containing divalproex are widely used for the treatment of seizures and bipolar disorder.
• Uses: Antiepileptic; Anticonvulsant that also acts as a mood stabilizer for those with bipolar disorder. Divalproex sodium consists of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form. In rare cases, it is also used as a treatment for major depressive disorder, and increasingly taken long-term for prevent Anticonvulsant; Bipolar Agent
• Therapeutic Function: Anticonvulsant
• Clinical Use: Treatment of manic episodes associated with bipolar disorder Migraine prophylaxis (unlicensed)
• Drug interactions: Potentially hazardous interactions with other drugs Antibacterials: metabolism possibly inhibited by erythromycin; avoid with pivmecillinam; concentration reduced by carbapenems - avoid. Antidepressants: avoid with St John’s wort. Antiepileptics: concentration reduced by carbamazepine; concentration of active carbamazepine metabolite increased; increased concentration of lamotrigine, phenobarbital, rufinamide and possibly ethosuximide; sometimes reduces concentration of active metabolite of oxcarbazepine; alters phenytoin concentration; phenytoin and phenobarbital reduce valproate concentration; hyperammonaemia and CNS toxicity with topiramate. Antipsychotics: increased neutropenia with olanzapine; possibly increases or decreases concentration of clozapine; possibly increases quetiapine concentration. Ciclosporin: variable ciclosporin blood level response. Sodium oxybate: concentration of sodium oxybate increased. Ulcer-healing drugs: metabolism inhibited by cimetidine, increased concentration.